Report

ORMP: Phase 2b Trial of ORMD-0801 Fully Enrolled; Data Expected 4Q19...

Underlying
Oramed Pharmaceuticals

Oramed Pharmaceuticals is a pharmaceutical company. The company is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company's primary product ORMD-0801, is an orally ingestible insulin capsule for the treatment of diabetes. In addition to its key product, the ORMD-0801 insulin capsule, the company is using its technology for an orally ingestible GLP-1 capsule, or ORMD-0901. The company is also developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule.

Provider
Zacks
Zacks

​Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

Other Reports on these Companies
Other Reports from Zacks

ResearchPool Subscriptions

Get the most out of your insights

Get in touch